Erectile Dysfunction
Peptides discussed for erectile dysfunction — PT-141 / bremelanotide (FDA-approved for HSDD), kisspeptin, and Vesilute. Mechanism, evidence, and how they relate to PDE5 inhibitors.
Erectile dysfunction (ED) affects roughly 30 million U.S. men, with prevalence rising sharply with age — about 40% of men over 40 report some degree of ED. The conventional treatment landscape is anchored by phosphodiesterase-5 (PDE5) inhibitors — sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil — which work by enhancing nitric-oxide-mediated smooth muscle relaxation in the corpus cavernosum. They are evidence-validated, FDA-approved, and effective in roughly 70-80% of men with ED. The remaining 20-30% — PDE5 non-responders — are the population for whom alternative approaches including peptide therapy become relevant.
The peptide most-discussed for ED is PT-141 (bremelanotide), a synthetic melanocortin receptor agonist that produces sexual response through central nervous system mechanisms rather than the peripheral vascular effects of PDE5 inhibitors. PT-141 is FDA-approved (as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women but is widely used off-label by men for ED, particularly by men who do not respond well to PDE5 inhibitors or who want a different mechanism. Kisspeptin and its derivatives target the upstream HPG axis and are at earlier stages of clinical development for sexual function indications. Vesilute is a PT-141 derivative.
This page covers what these peptides do, how they compare to PDE5 inhibitors, and the safety considerations specific to centrally-acting sexual-function peptides. The framing matters: ED with sudden onset, ED with concurrent cardiovascular symptoms, and ED in men who have not been screened for cardiovascular disease may be a marker for vascular pathology and needs medical evaluation, not just peptide self-treatment.
Peptides discussed for Erectile Dysfunction
PT-141 (Bremelanotide)
Melanocortin Receptor Agonist
An FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, also studied for broader sexual dysfunction.
Kisspeptin
Neuropeptide
A naturally occurring neuropeptide that plays a central role in reproductive hormone regulation and fertility.
Vesilute
Bioregulator Peptide
A synthetic dipeptide bioregulator (Glu-Asp) from the Khavinson system, studied for bladder function support, urinary health, and age-related urogenital decline.
How peptides target erectile dysfunction
Three peptides come up in ED discussions, all with mechanisms distinct from PDE5 inhibitors. First, PT-141 / bremelanotide is a 7-amino-acid cyclic synthetic peptide that activates melanocortin receptors — primarily MC4R in the central nervous system. Activation of MC4R in the hypothalamus produces a downstream cascade resulting in dopaminergic activation in the medial preoptic area and increased sexual response. Critically, PT-141 acts through central nervous system pathways and does not require functional vascular endothelium in the same way PDE5 inhibitors do — making it potentially useful in men whose ED is partly central or psychogenic, or whose vascular response to PDE5 inhibition is impaired.
Second, kisspeptin (the KISS1 gene product) is the master regulator of GnRH release and the gateway to the HPG (hypothalamic-pituitary-gonadal) axis. Exogenous kisspeptin administration upregulates LH and testosterone production and has been studied in hypogonadotropic hypogonadism, low libido, and as a possible adjunct to ED therapy. Clinical translation is in early stages; kisspeptin is administered intravenously or subcutaneously in research settings.
Third, Vesilute is a PT-141 derivative with similar mechanism marketed as a topical or sublingual ED option.
Two other peptides occasionally enter the conversation indirectly. Oxytocin has documented effects on social bonding and sexual response and is sometimes used adjunctively. Gonadorelin (a GnRH analog) restores HPG axis function in men with hypogonadotropic hypogonadism and indirectly improves ED secondary to low testosterone — though it is treating the underlying hypogonadism rather than ED per se.
What the evidence shows
PT-141 / bremelanotide has the most regulatory validation in this group. It is FDA-approved (2019) as Vyleesi for HSDD in premenopausal women, with Phase III randomized controlled trial evidence (the RECONNECT trials) showing modest but statistically significant improvement in desire and reduction of distress. The FDA approval is for women, but the mechanism (central melanocortin receptor activation) is non-sex-specific, and off-label use in men for ED has been substantial, with several published case series and at least one randomized controlled trial in men with ED showing improved erectile response.
Kisspeptin has been studied in human trials primarily for hypogonadotropic hypogonadism and women with delayed puberty or hypothalamic amenorrhea. Smaller studies have looked at kisspeptin effects on sexual response in men, with results suggesting it may have effects on desire and arousal beyond simple testosterone elevation. Clinical translation for ED is in early stages.
For men with PDE5-responsive ED, the evidence-validated approach remains PDE5 inhibitors — they have decades of randomized controlled trial evidence, FDA approval, and well-characterized efficacy and safety profiles. Peptides become more relevant for PDE5 non-responders, men with central or psychogenic ED, or men seeking alternatives to PDE5 inhibitors for tolerability reasons.
What to expect
PT-141 is most commonly used as a single subcutaneous injection 30-90 minutes before anticipated sexual activity, at doses of 1-2 mg. Reported response: meaningful sexual response in most users within the dosing window, lasting several hours. Common side effects include nausea (often significant — the most-reported adverse effect, sometimes severe enough that pre-medication or dose reduction is needed), facial flushing, transient hypertension in the hours after dose, and occasional darkening of skin pigmentation with frequent use. Some users tolerate it well; others find the side effect profile prohibitive.
Kisspeptin off-label use is much less established and dosing is largely investigational. Kisspeptin protocols are typically multi-week courses targeting underlying HPG axis function rather than acute pre-activity dosing.
General expectation setting: PT-141 is not a substitute for PDE5 inhibitors in men who respond well to them — PDE5 inhibitors are simpler, better-validated, more predictable, and have a more favorable side effect profile. PT-141 makes more sense for PDE5 non-responders or for men whose ED has prominent central/psychogenic features.
Important caveats
Sudden-onset ED, ED with chest pain, ED in men with uncontrolled hypertension or recent cardiac events, and ED with concurrent neurologic symptoms need medical evaluation before any peptide protocol — vascular and neurologic causes can be early markers of significant disease. PT-141 produces transient blood pressure elevation; men with uncontrolled hypertension or recent cardiovascular events should not use it. Concurrent use of PT-141 with PDE5 inhibitors has not been well-studied and is generally discouraged because of the divergent blood-pressure profiles. PT-141 is FDA-approved only for women's HSDD; off-label use in men is not regulated or studied to the same standard. Pregnancy and breastfeeding are contraindications. Men on testosterone therapy or clomiphene should discuss peptide protocols with their treating clinician.
Frequently asked questions
What is the best peptide for erectile dysfunction?
PT-141 / bremelanotide is the most-validated peptide in this space — FDA-approved for women's HSDD with Phase III evidence and substantial off-label use in men for ED. It works through a central nervous system mechanism distinct from PDE5 inhibitors. For most men with ED, the evidence-validated first-line remains PDE5 inhibitors (sildenafil, tadalafil, etc.). PT-141 is a reasonable consideration for PDE5 non-responders or for men seeking a different mechanism.
PT-141 vs Viagra — which is better?
Different mechanisms with different best-fit users. Viagra (sildenafil) and other PDE5 inhibitors enhance vascular response in the penis — they require some baseline nitric oxide signaling and respond well in most men with vascular ED. PT-141 acts through CNS melanocortin receptors and produces sexual response through central pathways — it works for some men who don't respond to PDE5 inhibitors, including some with psychogenic ED. PDE5 inhibitors have decades more clinical use and more predictable side effect profile. PT-141 is harder to dose and more often produces significant nausea. Most men with ED do better with a PDE5 inhibitor first.
How does PT-141 work?
PT-141 (bremelanotide) is a synthetic peptide that activates melanocortin receptors — primarily MC4R in the hypothalamus. MC4R activation triggers downstream dopaminergic activation in the medial preoptic area and other CNS regions involved in sexual response. The mechanism is distinct from PDE5 inhibition (which works peripherally on vascular smooth muscle). Because the mechanism is central, PT-141 can produce sexual response in men with vascular dysfunction that limits PDE5 inhibitor efficacy.
Is PT-141 safe?
PT-141 is FDA-approved (Vyleesi) for women's HSDD with established safety data in that population. Common side effects are significant in some users — nausea is the most-reported, sometimes severe enough to be limiting. Transient blood pressure elevation occurs in the hours after dose; men with uncontrolled hypertension or recent cardiovascular events should not use it. Long-term safety in male off-label use is less well-characterized than female on-label use. Skin pigmentation darkening can occur with frequent use due to MC1R activation.
Can I combine PT-141 with Cialis or Viagra?
Not recommended. PDE5 inhibitors lower blood pressure; PT-141 transiently raises it. Combining them produces unpredictable cardiovascular effects and has not been adequately studied. Most clinical guidance is to use one or the other, with at least 24 hours between if switching. Men with established cardiovascular disease should consult their cardiologist before any sexual-function pharmacotherapy.
Should I see a doctor before trying peptides for ED?
Yes. New-onset ED is sometimes an early marker for cardiovascular disease — endothelial dysfunction in penile vessels often precedes coronary symptoms by years. ED can also be a marker for diabetes, low testosterone, depression, or medication side effects. Basic workup (cardiovascular history, blood pressure, lipid panel, fasting glucose, total testosterone, depression screen, medication review) should precede peptide self-treatment. PDE5 inhibitors are generally considered first-line and should be tried under medical guidance before off-label peptides.
Part of these goals
Peptide families relevant to Erectile Dysfunction
Melanocortins
The peptide family of α-MSH analogs and selective melanocortin-receptor agonists — covering pigmentation (afamelanotide, melanotan-II), monogenic obesity (setmelanotide), and female sexual desire (bremelanotide / PT-141), plus the immunomodulatory KPV tripeptide and the cosmetic α-MSH analog nonapeptide-1.
GnRH Agonists & Antagonists
The peptide family of synthetic gonadotropin-releasing hormone (GnRH) agonists and antagonists — leuprolide, triptorelin, goserelin, buserelin, nafarelin, histrelin (agonists) and degarelix (antagonist) — used clinically for prostate cancer, endometriosis, central precocious puberty, and IVF cycle regulation. Plus the upstream master regulator kisspeptin and the diagnostic prototype gonadorelin.
Khavinson Bioregulators
A catalog of synthetic short peptides (typically 2-4 amino acids) developed at the St. Petersburg Institute of Bioregulation and Gerontology since the 1970s, positioned as tissue-specific epigenetic regulators of gene expression. The catalog spans 20+ entries — Epitalon, Cortagen, Pinealon, Vilon, Thymalin, Cardiogen, Bronchogen, and others — each targeted at a specific organ. A real Russian peer-reviewed literature with substantial preclinical depth, but a mechanistically speculative framework that has not been validated to mainstream Western molecular-biology standards.
Updated 2026-05-07